A Phase 2a Proof-of-Concept Study of R-107 for the Treatment of Refractory Major Depressive Disorder
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 13 Nov 2018
At a glance
- Drugs R 107 Radikal Therapeutics (Primary)
- Indications Major depressive disorder
- Focus Proof of concept; Therapeutic Use
- Acronyms BEDROC
- Sponsors Douglas Pharmaceuticals
- 13 Nov 2018 Planned End Date changed from 27 Sep 2019 to 6 Mar 2020.
- 13 Nov 2018 Planned initiation date changed from 27 Aug 2018 to 14 Jan 2019.
- 12 Nov 2018 Recruitment completion is expected on 15 Jan 2019.